SCHEMBL26109437

SCHEMBL26109437

C=CC(=O)N1CCC2(CC=C(c3c(C#N)c4c(N)ncnc4n3C)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 8/20 0.45
▸ DYRK1A Q13627 1/20 0.41
▸ NUDT14 O95848 1/20 0.40
▸ JAK2 O60674 5/20 0.40
▸ JAK3 P52333 5/20 0.40
▸ JAK1 P23458 2/20 0.40
▸ BTK Q06187 1/20 0.38
▸ FGFR1 P11362 4/20 0.38
▸ FGFR2 P21802 4/20 0.38
▸ FGFR3 P22607 4/20 0.38
▸ FGFR4 P22455 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30582497 0.88 NUDT14 (0.37) NUDT14JAK2JAK3JAK1BTK
SCHEMBL26107309 0.88 NUDT14 (0.37) NUDT14JAK2JAK3JAK1BTK
SCHEMBL26587626 0.86 NUDT14 (0.40) NUDT14JAK2JAK3JAK1BTK
SCHEMBL26588196 0.84 NUDT14 (0.39) NUDT14JAK2JAK3JAK1BTK
SCHEMBL30582533 0.84 ITK (0.42) NUDT14JAK2JAK3JAK1BTK
SCHEMBL30582629 0.83 NUDT14 (0.40) NUDT14JAK2JAK3JAK1BTK
SCHEMBL26589042 0.83 NUDT14 (0.40) NUDT14JAK2JAK3JAK1BTK
SCHEMBL30582526 0.82 JAK3 (0.49) NUDT14JAK2JAK3JAK1BTK
SCHEMBL30582511 0.82 JAK2 (0.38) NUDT14JAK2JAK3JAK1BTK
SCHEMBL30582502 0.82 FGFR1 (0.39) NUDT14JAK2JAK3JAK1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4499616-A1 SPIROBICYCLIC COMPOUNDS Acerand Therapeutics (Hong Kong) Limited (HK) 2025-02-05 — — EP disclosed
CN-119013260-A Spirobicyclic compounds 优领医药科技(香港)有限公司 2024-11-22 — — CN disclosed
WO-2024091370-A1 5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2024-05-02 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback